Data highlight safety profile of oral MS drug BG-12
Data highlight safety profile of oral MS drug BG-12
The latest data on Biogen Idec Inc.'s (BIIB) experimental multiple-sclerosis pill BG-12 show "favorable safety and tolerability" that support the drug's use as a front-line treatment for MS patients, the biotechnology company said.
Details from the "Confirm" study on BG-12 were set for presentation at an American Academy of Neurology conference Tuesday. The drug is currently under review with U.S. and European regulators and could be approved early next year.
Positive data and high expectations for the MS treatment have helped drive Biogen shares to around all-time high levels recently. Most treatments for the chronic, inflammatory and potentially disabling disease are delivered by needle, but BG-12 is an oral drug that will likely be taken twice daily.
The Biogen-funded Confirm study of about 1,400 MS patients showed the most common side effects for BG-12 patients at two years were flushing, or reddening of the skin, and gastrointestinal issues such as diarrhoea and nausea. These problems were more common with BG-12 than they were with a placebo, but the side effects "decreased substantially" for BG-12 patients after the first month of treatment, the company said.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1679
MS-UK - http://www.ms-uk.org/
-
- Family Elder
- Posts: 1161
- Joined: Thu Sep 14, 2006 2:00 pm
- Contact:
Re: Data highlight safety profile of oral MS drug BG-12
How much longer?
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1193 Views
-
Last post by frodo
-
- 0 Replies
- 2057 Views
-
Last post by NHE
-
- 0 Replies
- 1692 Views
-
Last post by Tif
-
- 1 Replies
- 1104 Views
-
Last post by Petr75
-
- 0 Replies
- 471 Views
-
Last post by NHE
-
- 0 Replies
- 1473 Views
-
Last post by NHE
-
- 1 Replies
- 2924 Views
-
Last post by Tif
-
- 2 Replies
- 855 Views
-
Last post by DIM
-
- 1 Replies
- 1796 Views
-
Last post by raceya